経口パーキンソン病治療薬の世界市場インサイト、2030年までの予測

Global Oral Parkinson's Disease Medications Market Insights, Forecast to 2030

経口パーキンソン病治療薬は、振戦、こわばり、徐脈などの運動症状を特徴とする神経変性疾患であるパーキンソン病の症状を管理するために経口投与される薬剤です。主な経口薬はレボドパで、しばしばカルビドパと... もっと見る

parkinsons disease

出版社	出版年月	電子版価格	言語
QYResearch QYリサーチ	2024年5月23日	US$4,900 シングルユーザライセンスライセンス・価格情報注文方法はこちら	英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

サマリー

経口パーキンソン病治療薬は、振戦、こわばり、徐脈などの運動症状を特徴とする神経変性疾患であるパーキンソン病の症状を管理するために経口投与される薬剤です。主な経口薬はレボドパで、しばしばカルビドパと併用され、脳内のドパミン濃度を高めて運動機能を改善する。その他の内服薬としては、ドパミンの作用を模倣するドパミンアゴニスト（例、プラミペキソール、ロピニロール）、ドパミンの分解を防ぐMAO-B阻害薬（例、セレギリン、ラサギリン）、レボドパの効果を延長させるCOMT阻害薬（例、エンタカポン）などがある。抗コリン薬（例、ベンズトロピン）やアマンタジンも特定の症状を管理するために使用される。これらの薬剤は、症状を軽減し、QOLを改善し、日常生活機能を向上させることを目的としていますが、病気を治癒させたり、進行を止めたりするものではありません。
世界の経口パーキンソン病治療薬市場は、予測期間中に年平均成長率（CAGR）%で、2024年の100万米ドルから2030年には100万米ドルに成長すると予測されている。

経口パーキンソン病治療薬の米国とカナダ市場は、2024年の100万米ドルから2030年には100万米ドルに達すると予測され、2024年から2030年の予測期間中に年平均成長率（CAGR）%で増加すると予測されています。
経口パーキンソン病治療薬の中国市場は、2024年の100万ドルから2030年には100万ドルに達すると推定され、2024年から2030年の予測期間中の年平均成長率は%である。
経口パーキンソン病治療薬のヨーロッパ市場は、2024年の100万ドルから2030年には100万ドルに達すると推定され、2024年から2030年までの予測期間中の年平均成長率は％である。
経口パーキンソン病治療薬の世界の主要メーカーには、AbbVie、Merck、Boehringer Ingelheim、GlaxoSmithKline、Novartis Pharma、Supernus Pharmaceuticals、Bausch Health、Newron Pharmaceuticals、Teva Pharmaceutica、Glenmark Pharmaceuticalsなどがあります。2023年、世界の上位5社の売上高シェアは約 %であった。

レポートの内容
経口パーキンソン病治療薬の世界市場概要、売上高、収益、価格などを紹介しています。2019年～2023年の過去の市場収益/売上データ、2024年の予測、2030年までのCAGR予測による世界市場動向の分析。
経口パーキンソン病治療薬の主要生産者を調査し、主要地域・国の売上高も掲載しています。経口パーキンソン病治療薬の今後の市場ポテンシャルと、この市場を様々なセグメントとサブセグメントに予測するための主要地域/国の注目点のハイライト。米国、カナダ、メキシコ、ブラジル、中国、日本、韓国、東南アジア、インド、ドイツ、英国、イタリア、中東、アフリカ、その他の国々の国別データと市場価値分析。

本レポートでは、経口パーキンソン病治療薬の売上高、収益、市場シェア、主要メーカーの業界ランキングに焦点を当て、2019年から2024年までのデータを掲載しています。世界の経口パーキンソン病治療薬市場における主要な利害関係者を特定し、その競争環境と市場ポジショニングを最近の動向とセグメント別の収益に基づいて分析します。本レポートは、利害関係者が競争状況を理解し、より多くの洞察を得て、より良い方法で事業と市場戦略を位置づけるのに役立ちます。
本レポートでは、2019年から2030年までのタイプ別、用途別のセグメントデータ、売上高、収益、価格を分析しています。経口パーキンソン病治療薬の売上高、予測成長動向、生産技術、用途、エンドユーザー産業の評価と市場規模予測。
AbbVie、Merck、Boehringer Ingelheim、GlaxoSmithKline、Novartis Pharma、Supernus Pharmaceuticals、Bausch Health、Newron Pharmaceuticals、Teva Pharmaceutica、Glenmark Pharmaceuticalsなど、世界の主要企業の詳細な企業プロフィール。

市場区分
企業別
アッヴィ
メルク
ベーリンガーインゲルハイム
グラクソ・スミスクライン
ノバルティスファーマ
スーパナス・ファーマシューティカルズ
ボシュ・ヘルス
ニューロン・ファーマシューティカルズ
テバ・ファーマスーティカ
グレンマーク製薬
オリオンファーマ
ニューロクライン・バイオサイエンス
協和キリン
UCB
デシチン
アムニール製薬
オルガノンファーマ
エフ・ホフマン・ラ・ロシュ
ルンドベック
スターダ
タイプ別セグメント
L-ドパ製剤
ドパミン作動薬
Mao-B阻害剤
COMT阻害剤
用途別セグメント
40歳未満
40～65歳
65歳以上
地域別セグメント
米国およびカナダ
米国
カナダ
中国
アジア（中国を除く）
日本
韓国
中国台湾
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
中東、アフリカ、中南米
ブラジル
メキシコ
トルコ
イスラエル
GCC諸国

各章の概要
第1章：報告書のスコープ、各市場セグメント（タイプ別、用途別など）の市場規模、今後の発展可能性などのエグゼクティブサマリーを紹介。市場の現状と、短期・中期・長期的な展開の可能性について、ハイレベルな見解を提供しています。
第2章経口パーキンソン病治療薬の世界、地域レベル、国レベルでの販売（消費）、収益。各地域と主要国の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場スペース、生産能力などを紹介しています。
第3章：経口パーキンソン病治療薬メーカーの競争環境、価格、売上高、市場シェア、業界ランキング、最新の開発計画、M&A情報などを詳細に分析。
第4章：各種市場セグメントをタイプ別に分析し、各市場セグメントの売上高、収益、平均価格、発展可能性などを網羅し、読者が各市場セグメントのブルーオーシャン市場を見つけやすくします。
第5章：読者が異なる下流市場のブルーオーシャン市場を見つけるのを助けるために、各市場セグメントの売上高、収益、平均価格、発展の可能性をカバーし、アプリケーション別に様々な市場セグメントの分析を提供します。
第6章北米（米国・カナダ）：タイプ別、用途別、国別、セグメント別の売上高、収益。
第7章：ヨーロッパ：タイプ別、用途別、国別、セグメント別の売上高、収益。
第8章：中国：タイプ別、用途別、セグメント別の売上高、収益。
第9章：アジア（中国を除く）：タイプ別、用途別、地域別、セグメント別の売上高、収益。
第10章：中東、アフリカ、中南米：タイプ別、用途別、国別、セグメント別の売上高、収益。
第11章：主要メーカーのプロファイルを提供し、製品の説明と仕様、経口パーキンソン病治療薬の売上高、収益、価格、粗利益率、最近の開発など、市場の主要企業の基本的な状況を詳細に紹介する。
第12章：産業チェーン、販売チャネル、主要原材料、流通業者、顧客の分析。
第13章：市場力学、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を紹介する。
第14章：レポートの要点と結論。

ページTOPに戻る

1 Study Coverage
1.1 Oral Parkinson's Disease Medications Product Introduction
1.2 Market by Type
1.2.1 Global Oral Parkinson's Disease Medications Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 L-Dopa Formulations
1.2.3 Dopamine Agonists
1.2.4 Mao-B Inhibitors
1.2.5 COMT Inhibitors
1.3 Market by Application
1.3.1 Global Oral Parkinson's Disease Medications Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Under 40 Years Old
1.3.3 40-65 Years Old
1.3.4 Above 65 Years Old
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Oral Parkinson's Disease Medications Revenue Estimates and Forecasts 2019-2030
2.2 Global Oral Parkinson's Disease Medications Revenue by Region
2.2.1 Global Oral Parkinson's Disease Medications Revenue by Region: 2019 VS 2023 VS 2030
2.2.2 Global Oral Parkinson's Disease Medications Revenue by Region (2019-2024)
2.2.3 Global Oral Parkinson's Disease Medications Revenue by Region (2025-2030)
2.2.4 Global Oral Parkinson's Disease Medications Revenue Market Share by Region (2019-2030)
2.3 Global Oral Parkinson's Disease Medications Sales Estimates and Forecasts 2019-2030
2.4 Global Oral Parkinson's Disease Medications Sales by Region
2.4.1 Global Oral Parkinson's Disease Medications Sales by Region: 2019 VS 2023 VS 2030
2.4.2 Global Oral Parkinson's Disease Medications Sales by Region (2019-2024)
2.4.3 Global Oral Parkinson's Disease Medications Sales by Region (2025-2030)
2.4.4 Global Oral Parkinson's Disease Medications Sales Market Share by Region (2019-2030)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Oral Parkinson's Disease Medications Sales by Manufacturers
3.1.1 Global Oral Parkinson's Disease Medications Sales by Manufacturers (2019-2024)
3.1.2 Global Oral Parkinson's Disease Medications Sales Market Share by Manufacturers (2019-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Oral Parkinson's Disease Medications in 2023
3.2 Global Oral Parkinson's Disease Medications Revenue by Manufacturers
3.2.1 Global Oral Parkinson's Disease Medications Revenue by Manufacturers (2019-2024)
3.2.2 Global Oral Parkinson's Disease Medications Revenue Market Share by Manufacturers (2019-2024)
3.2.3 Global Top 10 and Top 5 Companies by Oral Parkinson's Disease Medications Revenue in 2023
3.3 Global Key Players of Oral Parkinson's Disease Medications, Industry Ranking, 2021 VS 2022
3.4 Global Oral Parkinson's Disease Medications Sales Price by Manufacturers (2019-2024)
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Oral Parkinson's Disease Medications Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Oral Parkinson's Disease Medications, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Oral Parkinson's Disease Medications, Product Offered and Application
3.8 Global Key Manufacturers of Oral Parkinson's Disease Medications, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Oral Parkinson's Disease Medications Sales by Type
4.1.1 Global Oral Parkinson's Disease Medications Historical Sales by Type (2019-2024)
4.1.2 Global Oral Parkinson's Disease Medications Forecasted Sales by Type (2025-2030)
4.1.3 Global Oral Parkinson's Disease Medications Sales Market Share by Type (2019-2030)
4.2 Global Oral Parkinson's Disease Medications Revenue by Type
4.2.1 Global Oral Parkinson's Disease Medications Historical Revenue by Type (2019-2024)
4.2.2 Global Oral Parkinson's Disease Medications Forecasted Revenue by Type (2025-2030)
4.2.3 Global Oral Parkinson's Disease Medications Revenue Market Share by Type (2019-2030)
4.3 Global Oral Parkinson's Disease Medications Price by Type
4.3.1 Global Oral Parkinson's Disease Medications Price by Type (2019-2024)
4.3.2 Global Oral Parkinson's Disease Medications Price Forecast by Type (2025-2030)
5 Market Size by Application
5.1 Global Oral Parkinson's Disease Medications Sales by Application
5.1.1 Global Oral Parkinson's Disease Medications Historical Sales by Application (2019-2024)
5.1.2 Global Oral Parkinson's Disease Medications Forecasted Sales by Application (2025-2030)
5.1.3 Global Oral Parkinson's Disease Medications Sales Market Share by Application (2019-2030)
5.2 Global Oral Parkinson's Disease Medications Revenue by Application
5.2.1 Global Oral Parkinson's Disease Medications Historical Revenue by Application (2019-2024)
5.2.2 Global Oral Parkinson's Disease Medications Forecasted Revenue by Application (2025-2030)
5.2.3 Global Oral Parkinson's Disease Medications Revenue Market Share by Application (2019-2030)
5.3 Global Oral Parkinson's Disease Medications Price by Application
5.3.1 Global Oral Parkinson's Disease Medications Price by Application (2019-2024)
5.3.2 Global Oral Parkinson's Disease Medications Price Forecast by Application (2025-2030)
6 US & Canada
6.1 US & Canada Oral Parkinson's Disease Medications Market Size by Type
6.1.1 US & Canada Oral Parkinson's Disease Medications Sales by Type (2019-2030)
6.1.2 US & Canada Oral Parkinson's Disease Medications Revenue by Type (2019-2030)
6.2 US & Canada Oral Parkinson's Disease Medications Market Size by Application
6.2.1 US & Canada Oral Parkinson's Disease Medications Sales by Application (2019-2030)
6.2.2 US & Canada Oral Parkinson's Disease Medications Revenue by Application (2019-2030)
6.3 US & Canada Oral Parkinson's Disease Medications Market Size by Country
6.3.1 US & Canada Oral Parkinson's Disease Medications Revenue by Country: 2019 VS 2023 VS 2030
6.3.2 US & Canada Oral Parkinson's Disease Medications Revenue by Country (2019-2030)
6.3.3 US & Canada Oral Parkinson's Disease Medications Sales by Country (2019-2030)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Oral Parkinson's Disease Medications Market Size by Type
7.1.1 Europe Oral Parkinson's Disease Medications Sales by Type (2019-2030)
7.1.2 Europe Oral Parkinson's Disease Medications Revenue by Type (2019-2030)
7.2 Europe Oral Parkinson's Disease Medications Market Size by Application
7.2.1 Europe Oral Parkinson's Disease Medications Sales by Application (2019-2030)
7.2.2 Europe Oral Parkinson's Disease Medications Revenue by Application (2019-2030)
7.3 Europe Oral Parkinson's Disease Medications Market Size by Country
7.3.1 Europe Oral Parkinson's Disease Medications Revenue by Country: 2019 VS 2023 VS 2030
7.3.2 Europe Oral Parkinson's Disease Medications Revenue by Country (2019-2030)
7.3.3 Europe Oral Parkinson's Disease Medications Sales by Country (2019-2030)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Oral Parkinson's Disease Medications Market Size by Type
8.1.1 China Oral Parkinson's Disease Medications Sales by Type (2019-2030)
8.1.2 China Oral Parkinson's Disease Medications Revenue by Type (2019-2030)
8.2 China Oral Parkinson's Disease Medications Market Size by Application
8.2.1 China Oral Parkinson's Disease Medications Sales by Application (2019-2030)
8.2.2 China Oral Parkinson's Disease Medications Revenue by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Oral Parkinson's Disease Medications Market Size by Type
9.1.1 Asia Oral Parkinson's Disease Medications Sales by Type (2019-2030)
9.1.2 Asia Oral Parkinson's Disease Medications Revenue by Type (2019-2030)
9.2 Asia Oral Parkinson's Disease Medications Market Size by Application
9.2.1 Asia Oral Parkinson's Disease Medications Sales by Application (2019-2030)
9.2.2 Asia Oral Parkinson's Disease Medications Revenue by Application (2019-2030)
9.3 Asia Oral Parkinson's Disease Medications Market Size by Region
9.3.1 Asia Oral Parkinson's Disease Medications Revenue by Region: 2019 VS 2023 VS 2030
9.3.2 Asia Oral Parkinson's Disease Medications Revenue by Region (2019-2030)
9.3.3 Asia Oral Parkinson's Disease Medications Sales by Region (2019-2030)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
9.3.9 Australia
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Oral Parkinson's Disease Medications Market Size by Type
10.1.1 Middle East, Africa and Latin America Oral Parkinson's Disease Medications Sales by Type (2019-2030)
10.1.2 Middle East, Africa and Latin America Oral Parkinson's Disease Medications Revenue by Type (2019-2030)
10.2 Middle East, Africa and Latin America Oral Parkinson's Disease Medications Market Size by Application
10.2.1 Middle East, Africa and Latin America Oral Parkinson's Disease Medications Sales by Application (2019-2030)
10.2.2 Middle East, Africa and Latin America Oral Parkinson's Disease Medications Revenue by Application (2019-2030)
10.3 Middle East, Africa and Latin America Oral Parkinson's Disease Medications Market Size by Country
10.3.1 Middle East, Africa and Latin America Oral Parkinson's Disease Medications Revenue by Country: 2019 VS 2023 VS 2030
10.3.2 Middle East, Africa and Latin America Oral Parkinson's Disease Medications Revenue by Country (2019-2030)
10.3.3 Middle East, Africa and Latin America Oral Parkinson's Disease Medications Sales by Country (2019-2030)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Corporate Profile
11.1 AbbVie
11.1.1 AbbVie Company Information
11.1.2 AbbVie Overview
11.1.3 AbbVie Oral Parkinson's Disease Medications Sales, Price, Revenue and Gross Margin (2019-2024)
11.1.4 AbbVie Oral Parkinson's Disease Medications Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 AbbVie Recent Developments
11.2 Merck
11.2.1 Merck Company Information
11.2.2 Merck Overview
11.2.3 Merck Oral Parkinson's Disease Medications Sales, Price, Revenue and Gross Margin (2019-2024)
11.2.4 Merck Oral Parkinson's Disease Medications Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Merck Recent Developments
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Company Information
11.3.2 Boehringer Ingelheim Overview
11.3.3 Boehringer Ingelheim Oral Parkinson's Disease Medications Sales, Price, Revenue and Gross Margin (2019-2024)
11.3.4 Boehringer Ingelheim Oral Parkinson's Disease Medications Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Boehringer Ingelheim Recent Developments
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Information
11.4.2 GlaxoSmithKline Overview
11.4.3 GlaxoSmithKline Oral Parkinson's Disease Medications Sales, Price, Revenue and Gross Margin (2019-2024)
11.4.4 GlaxoSmithKline Oral Parkinson's Disease Medications Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 GlaxoSmithKline Recent Developments
11.5 Novartis Pharma
11.5.1 Novartis Pharma Company Information
11.5.2 Novartis Pharma Overview
11.5.3 Novartis Pharma Oral Parkinson's Disease Medications Sales, Price, Revenue and Gross Margin (2019-2024)
11.5.4 Novartis Pharma Oral Parkinson's Disease Medications Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Novartis Pharma Recent Developments
11.6 Supernus Pharmaceuticals
11.6.1 Supernus Pharmaceuticals Company Information
11.6.2 Supernus Pharmaceuticals Overview
11.6.3 Supernus Pharmaceuticals Oral Parkinson's Disease Medications Sales, Price, Revenue and Gross Margin (2019-2024)
11.6.4 Supernus Pharmaceuticals Oral Parkinson's Disease Medications Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Supernus Pharmaceuticals Recent Developments
11.7 Bausch Health
11.7.1 Bausch Health Company Information
11.7.2 Bausch Health Overview
11.7.3 Bausch Health Oral Parkinson's Disease Medications Sales, Price, Revenue and Gross Margin (2019-2024)
11.7.4 Bausch Health Oral Parkinson's Disease Medications Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Bausch Health Recent Developments
11.8 Newron Pharmaceuticals
11.8.1 Newron Pharmaceuticals Company Information
11.8.2 Newron Pharmaceuticals Overview
11.8.3 Newron Pharmaceuticals Oral Parkinson's Disease Medications Sales, Price, Revenue and Gross Margin (2019-2024)
11.8.4 Newron Pharmaceuticals Oral Parkinson's Disease Medications Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Newron Pharmaceuticals Recent Developments
11.9 Teva Pharmaceutica
11.9.1 Teva Pharmaceutica Company Information
11.9.2 Teva Pharmaceutica Overview
11.9.3 Teva Pharmaceutica Oral Parkinson's Disease Medications Sales, Price, Revenue and Gross Margin (2019-2024)
11.9.4 Teva Pharmaceutica Oral Parkinson's Disease Medications Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Teva Pharmaceutica Recent Developments
11.10 Glenmark Pharmaceuticals
11.10.1 Glenmark Pharmaceuticals Company Information
11.10.2 Glenmark Pharmaceuticals Overview
11.10.3 Glenmark Pharmaceuticals Oral Parkinson's Disease Medications Sales, Price, Revenue and Gross Margin (2019-2024)
11.10.4 Glenmark Pharmaceuticals Oral Parkinson's Disease Medications Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Glenmark Pharmaceuticals Recent Developments
11.11 Orion Pharma
11.11.1 Orion Pharma Company Information
11.11.2 Orion Pharma Overview
11.11.3 Orion Pharma Oral Parkinson's Disease Medications Sales, Price, Revenue and Gross Margin (2019-2024)
11.11.4 Orion Pharma Oral Parkinson's Disease Medications Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Orion Pharma Recent Developments
11.12 Neurocrine Biosciences
11.12.1 Neurocrine Biosciences Company Information
11.12.2 Neurocrine Biosciences Overview
11.12.3 Neurocrine Biosciences Oral Parkinson's Disease Medications Sales, Price, Revenue and Gross Margin (2019-2024)
11.12.4 Neurocrine Biosciences Oral Parkinson's Disease Medications Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Neurocrine Biosciences Recent Developments
11.13 Kyowa Kirin
11.13.1 Kyowa Kirin Company Information
11.13.2 Kyowa Kirin Overview
11.13.3 Kyowa Kirin Oral Parkinson's Disease Medications Sales, Price, Revenue and Gross Margin (2019-2024)
11.13.4 Kyowa Kirin Oral Parkinson's Disease Medications Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Kyowa Kirin Recent Developments
11.14 UCB
11.14.1 UCB Company Information
11.14.2 UCB Overview
11.14.3 UCB Oral Parkinson's Disease Medications Sales, Price, Revenue and Gross Margin (2019-2024)
11.14.4 UCB Oral Parkinson's Disease Medications Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 UCB Recent Developments
11.15 Desitin Arzneimittel
11.15.1 Desitin Arzneimittel Company Information
11.15.2 Desitin Arzneimittel Overview
11.15.3 Desitin Arzneimittel Oral Parkinson's Disease Medications Sales, Price, Revenue and Gross Margin (2019-2024)
11.15.4 Desitin Arzneimittel Oral Parkinson's Disease Medications Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Desitin Arzneimittel Recent Developments
11.16 Amneal Pharmaceuticals
11.16.1 Amneal Pharmaceuticals Company Information
11.16.2 Amneal Pharmaceuticals Overview
11.16.3 Amneal Pharmaceuticals Oral Parkinson's Disease Medications Sales, Price, Revenue and Gross Margin (2019-2024)
11.16.4 Amneal Pharmaceuticals Oral Parkinson's Disease Medications Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Amneal Pharmaceuticals Recent Developments
11.17 Organon Pharma
11.17.1 Organon Pharma Company Information
11.17.2 Organon Pharma Overview
11.17.3 Organon Pharma Oral Parkinson's Disease Medications Sales, Price, Revenue and Gross Margin (2019-2024)
11.17.4 Organon Pharma Oral Parkinson's Disease Medications Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Organon Pharma Recent Developments
11.18 F.Hoffmann-La Roche
11.18.1 F.Hoffmann-La Roche Company Information
11.18.2 F.Hoffmann-La Roche Overview
11.18.3 F.Hoffmann-La Roche Oral Parkinson's Disease Medications Sales, Price, Revenue and Gross Margin (2019-2024)
11.18.4 F.Hoffmann-La Roche Oral Parkinson's Disease Medications Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 F.Hoffmann-La Roche Recent Developments
11.19 Lundbeck
11.19.1 Lundbeck Company Information
11.19.2 Lundbeck Overview
11.19.3 Lundbeck Oral Parkinson's Disease Medications Sales, Price, Revenue and Gross Margin (2019-2024)
11.19.4 Lundbeck Oral Parkinson's Disease Medications Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 Lundbeck Recent Developments
11.20 Stada
11.20.1 Stada Company Information
11.20.2 Stada Overview
11.20.3 Stada Oral Parkinson's Disease Medications Sales, Price, Revenue and Gross Margin (2019-2024)
11.20.4 Stada Oral Parkinson's Disease Medications Product Model Numbers, Pictures, Descriptions and Specifications
11.20.5 Stada Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Oral Parkinson's Disease Medications Industry Chain Analysis
12.2 Oral Parkinson's Disease Medications Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Oral Parkinson's Disease Medications Production Mode & Process
12.4 Oral Parkinson's Disease Medications Sales and Marketing
12.4.1 Oral Parkinson's Disease Medications Sales Channels
12.4.2 Oral Parkinson's Disease Medications Distributors
12.5 Oral Parkinson's Disease Medications Customers
13 Oral Parkinson's Disease Medications Market Dynamics
13.1 Oral Parkinson's Disease Medications Industry Trends
13.2 Oral Parkinson's Disease Medications Market Drivers
13.3 Oral Parkinson's Disease Medications Market Challenges
13.4 Oral Parkinson's Disease Medications Market Restraints
14 Key Findings in the Global Oral Parkinson's Disease Medications Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
15.3 Disclaimer

ページTOPに戻る

Table of Contents

Summary

Oral Parkinson's disease medications are drugs taken by mouth to manage the symptoms of Parkinson's disease, a neurodegenerative disorder characterized by motor symptoms such as tremors, stiffness, and bradykinesia (slowed movements). The primary oral medication is levodopa, often combined with carbidopa, which helps increase dopamine levels in the brain and improve motor function. Other oral medications include dopamine agonists (e.g., pramipexole, ropinirole) that mimic dopamine effects, MAO-B inhibitors (e.g., selegiline, rasagiline) that prevent dopamine breakdown, and COMT inhibitors (e.g., entacapone) that prolong the effect of levodopa. Anticholinergics (e.g., benztropine) and amantadine are also used to manage specific symptoms. These medications aim to reduce symptoms, improve quality of life, and enhance daily functioning, although they do not cure the disease or stop its progression.
The global Oral Parkinson's Disease Medications market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of %during the forecast period.

The US & Canada market for Oral Parkinson's Disease Medications is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The China market for Oral Parkinson's Disease Medications is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The Europe market for Oral Parkinson's Disease Medications is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key manufacturers of Oral Parkinson's Disease Medications include AbbVie, Merck, Boehringer Ingelheim, GlaxoSmithKline, Novartis Pharma, Supernus Pharmaceuticals, Bausch Health, Newron Pharmaceuticals, Teva Pharmaceutica, Glenmark Pharmaceuticals, etc. In 2023, the global top five players had a share approximately % in terms of revenue.

Report Includes
This report presents an overview of global market for Oral Parkinson's Disease Medications, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Oral Parkinson's Disease Medications, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Oral Parkinson's Disease Medications, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oral Parkinson's Disease Medications sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Oral Parkinson's Disease Medications market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Oral Parkinson's Disease Medications sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including AbbVie, Merck, Boehringer Ingelheim, GlaxoSmithKline, Novartis Pharma, Supernus Pharmaceuticals, Bausch Health, Newron Pharmaceuticals, Teva Pharmaceutica, Glenmark Pharmaceuticals, etc.

Market Segmentation
By Company
AbbVie
Merck
Boehringer Ingelheim
GlaxoSmithKline
Novartis Pharma
Supernus Pharmaceuticals
Bausch Health
Newron Pharmaceuticals
Teva Pharmaceutica
Glenmark Pharmaceuticals
Orion Pharma
Neurocrine Biosciences
Kyowa Kirin
UCB
Desitin Arzneimittel
Amneal Pharmaceuticals
Organon Pharma
F.Hoffmann-La Roche
Lundbeck
Stada
Segment by Type
L-Dopa Formulations
Dopamine Agonists
Mao-B Inhibitors
COMT Inhibitors
Segment by Application
Under 40 Years Old
40-65 Years Old
Above 65 Years Old
Segment by region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Australia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Oral Parkinson's Disease Medications in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Oral Parkinson's Disease Medications manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oral Parkinson's Disease Medications sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療/ヘルスケア）の最新刊レポート

QYResearch社の医薬・ヘルスケア分野での最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

QYResearch社はどのような調査会社ですか?

QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

経口パーキンソン病治療薬の世界市場インサイト、2030年までの予測

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医療/ヘルスケア）の最新刊レポート

QYResearch社の医薬・ヘルスケア分野での最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

よくあるご質問

QYResearch社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?